Ana
Fernández Montes
Complexo Hospitalario Universitario de Pontevedra
Pontevedra, EspañaPublicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Pontevedra (8)
2024
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
2022
-
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 1209-1214
2021
-
Dynamic perspective of the neutrophil-to-lymphocyte ratio in metastatic gastric cancer
Journal of B.U.ON., Vol. 26, Núm. 5, pp. 2131-2140
-
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
BMC Cancer, Vol. 21, Núm. 1
-
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Scientific Reports, Vol. 11, Núm. 1
-
Real-life use of ramucirumab in gastric cancer in Spain: The RAMIS study
Future Oncology, Vol. 17, Núm. 14, pp. 1777-1791
2020
-
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 351-359